Virosome studied by MedImmune

By Dylan Bushell-Embling
Friday, 18 July, 2008

Technology developed by Norwood Abbey's [ASX: NAL] second-tier subsidiary Virosome Biologicals is being evaluated by US company MedImmune.

The companies have signed a six-month exclusive evaluation agreement over Virosome's virosomal vaccine technology. In this time the companies will collaborate on research using the virosome technology with MedImmune vaccine candidates.

MedImmune is a member of the AstraZeneca group.

NSW Govt delivers foot-and-mouth vaccine to protect livestock

A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...

Scientists optimise delivery of mRNA to target cells

A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...

'Anti-reward' brain network helps explain cocaine addiction

A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...

Content from other channels on our network

ARENA launches battery manufacturing grant program

WA hot briquetted iron plant gets EPA approval

Rockwell appoints Applied Robotics as AMR partner

Carbon280 launches pilot plant for hydrogen storage technology

ARENA supports rail charging solution for heavy mining vehicles

Could rapeseed be the next vegan protein?

Fonterra increases its farmgate milk price forecast

Biofoam box project provides eco seafood storage

Food and grocery sector records impressive growth

SA winery opts for bulk bag discharging

[New Zealand] Transform from Security Awareness to a Security Culture: A Vital Shift for SMB Healthcare — Webinar

WA establishes $50m older hospitals maintenance fund

Clinical Safety in Digital Health — Introductory eLearning course launches

Victoria's first Chief Palliative Care Adviser to oversee framework refresh

NHS hospital pilots AI in discharge summaries